TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bone age of the wrist and hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in Ki67 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of corneal surface in the diseased eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of corneal surface in the fellow eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in perceptions of epidural
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change from baseline in annexin V positive microvesicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in microvesicles derived miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Erectile Function (EF) domain score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Correlation between the COMI and RMDQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Oswestry Disability Index Score v2.1a
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recovery of shoulder range of movements (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevention of arm lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IADL (Instrumental Activities of Daily Living) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Evaluation of safety
Endpoint domain: Adverse events/effects
Primary endpoint: Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulation of inflammatory reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activity of acute phase protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Intra-hepatocellular Lipid Content (IHCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of Combination Therapy vs Cryotherapy Alone
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving ASAS20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants With an Objective Response of Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Reduction in Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Vital Signs: Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change From Baseline in Liver Fat on Magnetic Resonance Imaging- Proton Density Fat Fraction (MRI-PDFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Diabetes Distress Scale (DDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with at least one adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of combination of olaparib and carboplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Cisplatin concentration in the superficial chest wall tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with Grade 3 or greater treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma pharmacokinetic parameters (Cmax, Cmin, tmax, AUC0→τ, AUC0→∞, t1/2, CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular pharmacokinetic parameters (Cmax, Cmin, tmax, AUC0→τ, AUC0→∞, t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return-of-spontaneous-circulation (ROSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of oropharyngeal candidiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severity of URTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Break Up Time Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NF-kB translocation in lymphocyte populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PASI (Psoriasis Area Severity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: BSA (Body Surface Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical Resolution of Skin Abscess
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Long-term outcome of use of Fenestrated Anaconda
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: excyclotorsion in degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of major depressive disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients dead or alive
Endpoint domain: Mortality/survival
Primary endpoint: Weekly weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight relapse after 36 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unstable angina for which hospital admission required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Novel biomarkers for adnexal mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general quality of life scale index and general quality of life scale vas scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: compliance with medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body mass index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's global feeling
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient's physical feeling
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Corneal Infiltrate Events
Endpoint domain: Adverse events/effects
Primary endpoint: International Restless Legs Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak brain uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-stability of distribution volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of specific to non-displaceable brain uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of immediate nausea or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sinus CT opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily compliance in physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in the frequency of asthma attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in admission to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Central corneal endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life (QOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immune subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom From Progression at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective measures of brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of successful imaging attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Preoperative Preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Subjective Dysphagia Assessment Score: EAT-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory-confirmed Influenza Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Impact on complications
Endpoint domain: Adverse events/effects
Primary endpoint: HFOV oxygen saturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory system tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Major atherothrombotic events
Endpoint domain: Mortality/survival
Primary endpoint: Internalised stigma of mental illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of AEs and SAEs in healthy volunteers
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of AEs and SAEs in pregnant subjects and the fetus or infant
Endpoint domain: Adverse events/effects
Primary endpoint: Cost per case at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dose Limiting Toxicity (DLT) of MBS301
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of MBS301
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive disorder assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: serum biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of occurrence of atrial high rate episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3 hour area under the curve from baseline following a standardized breakfast meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: daytime average glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent of CGMS glucose values in range (70-180 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of alcoholic relapses
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of medication histories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test of Adolescent Social Skills Knowledge (TASSK)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social Responsiveness Scale (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Michigan Hand Questionnaire Total Score (MHQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Discharge times from the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Healthy Eating Index 2010 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cross-sectional area of POSEH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-care power
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Brain MRI lesion activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient preference between TKA and UKA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Connor-Davidson Resilience Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Levels of IL-6/sIL-6R Complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of C-reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recovery Total Quality Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ability of Peposertib (M3814) to cross the blood brain barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinician Administered PTSD Scale (CAPS-5) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale 6 item version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survival with neurodevelopmental impairment
Endpoint domain: Mortality/survival
Primary endpoint: Change in error related negativity (ERN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NoGo N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NoGo P3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Greater Than or Equal to (>=) Grade 4 Toxicity in Laboratory Tests
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-last]) for Single Dose of Lazertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biological potency of DBV712-IHRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in National Institutes of Health Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Unplanned hospitalizations for CHF with hospital stay > 1 day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Non-programmed emergency department admission related to CHF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage change in corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with >= 50% change in prednisone dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUVratio of FECH PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of Intensive Care Unit stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postprandial Glycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lifespan patency
Endpoint domain: Mortality/survival
Primary endpoint: Ability to complete HD session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of women who complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Repolarization alternans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative number of new T2 hyperintensive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serology for HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serology for HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serology for HAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IOP Change From Baseline at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: General Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Erythropoietin Responsiveness factor (EPO index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Toxicity grading
Endpoint domain: Adverse events/effects
Primary endpoint: Improved Fatigue Experience
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Total fluorescein corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease-free survival at 2 and 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Safety of arsenic trioxide following cytarabine and anthracycline
Endpoint domain: Adverse events/effects
Primary endpoint: Conception rate of women attempting pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Overall conception rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Local disease control rate (short-term failure of hysteroscopic resection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distant disease control rate (long-term failure of hysteroscopic resection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of subjects return to room air (RTRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fruit & vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spectral quality (linewidth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Tissue Content of Deoxyhemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hand Washing Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Prognostic Value (NPV)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Maintenance of hemoglobin >/=10.5 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Zubrod Performance Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative post-chemoradiation PET/MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Fruit Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported Vegetable Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Modified Ashworth Scale (MAS) Ankle Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in cervical range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain perception
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in Neck Pain and Disability Perception
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activity-Role Adequacy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: percentage of corneal pterygium area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adverse events of ES101
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of adverse events of ES101
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients aware of incurability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healing of the fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: qNOX index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9-item Patient Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 10-item Geriatric Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-compassion scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inhaler adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of Henagliflozin Proline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css, max of Henagliflozin Proline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of Hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css, max of Hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-evaluation of appetite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status